Search results
Showing 1 to 3 of 3 results for icosapent
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)
This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.
Hundreds of thousands set to benefit from new treatment to prevent heart attacks and strokes
NICE has published final draft guidance which recommends icosapent ethyl for reducing the risk of heart attacks and strokes in adults who have raised blood fats.